Sociedad Americana de Hirudoterapia

The IL-1 cytokine family and its role in inflammation and fibrosis in the lung

Review published in Seminars in immunopathology (2016)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDesarrollo de fármacosBorthwick LA · Seminars in immunopathology, 2016

Abstract

The IL-1 cytokine family comprises 11 members (7 ligands with agonist activity, 3 receptor antagonists and 1 anti-inflammatory cytokine) and is recognised as a key mediator of inflammation and fibrosis in multiple tissues including the lung. IL-1 targeted therapies have been successfully employed to treat a range of inflammatory conditions such as rheumatoid arthritis and gouty arthritis. This review will introduce the members of the IL-1 cytokine family, briefly discuss the cellular origins and cellular targets and provide an overview of the role of these molecules in inflammation and fibrosis in the lung.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReviewResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsCytokinesFibrosisHumansInflammationInflammation MediatorsInterleukin-1Lung DiseasesReceptors, Interleukin-1Risk FactorsSignal Transduction

Resumen

The IL-1 cytokine family comprises 11 members (7 ligands with agonist activity, 3 receptor antagonists and 1 anti-inflammatory cytokine) and is recognised as a key mediator of inflammation and fibrosis in multiple tissues including the lung.

Por qué esto importa para la hirudoterapia

Contributes clinical or preclinical evidence relevant to leech therapy and its derived bioactive compounds.

Citación

The IL-1 cytokine family and its role in inflammation and fibrosis in the lung

Borthwick LA · Seminars in immunopathology, 2016

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.